For patients who had at least 1 year of follow up after stopping antibiotics (pulmonary n = 21, non-pulmonary n = 14), 43% of patients with pulmonary infections achieved clinical cure and 79% of patients with non-pulmonary infections achieved clinical cure. Within 1 year of follow-up 19% of pulmonary infection patients and none of the non-pulmonary patients had died.
Background. 178 new cases of leprosy were reported in 2015 with Florida being one of six states and contributing a large number (72%) of registered cases. It was also the only state showing an increasing occurrence compared with the previous years. Studies from other southern U.S. states in armadillos and leprosy patients demonstrate infection with the same strain of Mycobacterium leprae, confirming human armadillo exposure as the main risk factor for leprosy. In contrast, cases from Florida show no clear risk factor. We present three cases of leprosy from Hillsborough county (Florida) with no previous armadillo exposure but a different risk factor in common: being foreign-born.
Methods. We report three cases of leprosy presenting in a non-endemic area of Florida during the past five years and highlight the absence of direct armadillo exposure as a risk factor for developing the disease.
Results. Case 1: A 35-year-old male from Mexico presented with multiple erythematous non-tender cutaneous lesions and numbness in both hands. He had a history of leprosy exposure from a Haitian inmate during incarceration in Florida. Biopsy confirmed borderline lepromatous leprosy.
Case 2: A 67-year-old female from Cuba presented with disseminated circular ulcerative lesions and severe hypesthesia of lower extremities. She denied leprosy or armadillo exposure. Diagnosis of borderline lepromatous leprosy was made through biopsy.
Case 3: A 38-year-old female from Puerto Rico presented with disseminated painless plaques, edema of the hands with numbness and paresthesias. She worked as a nurse but denied leprosy or armadillo exposure. A biopsy confirmed borderline lepromatous leprosy with erythema nodosum leprosum.
Conclusion. Our case series demonstrates that a history of armadillo exposure is not always present. Other risk factors need to be considered when leprosy is a possible diagnosis in a patient. Place of birth is a very important factor due to the diverse and increasing foreign-born population in the United States.
Disclosures. Methods. Patient (N = 1039) pharmacy claims at year 1 following NTMLD diagnosis were classified into 3 treatment groups including triple combo (macrolide + ethambutol + rifamycin ± other drugs) (G1), other antibiotics used by physicians for NTMLD (G2), and no treatment (G3). Hospitalization rates at year 2 were compared between treatment groups using mixed effects logistic regression to adjust for patient characteristics and comorbidities measured by Charlson Comorbidity Index (CCI) during the 12 months prior to NTMLD diagnosis (baseline).
Results. Mean age was 66, 66 and 73 years with 65%, 70% and 66% women in G1 (n = 353), G2 (n = 388) and G3 (n = 298) respectively. At baseline, there was no difference on CCI (CCI≈2) between treatment groups. However, comorbidity distribution differed prominently in asthma (22.1%, 26.3% and 11.4%), arrhythmia (19.3%, 19.3% and 27.2%), cystic fibrosis (0.8%, 4.6% and 0%), immune disorder (7.6%, 9% and 2.7%), pneumonia (49.0%, 41.8% and 32.6%), and tuberculosis (9.3%, 8.2% and 5.4%), and in immunosuppressant use (51%, 51.5% and 25.2%). Baseline hospitalization was 31.7% in G1, 33.0% in G2, and 25.8% in G3. At year 2, CCI stayed almost unchanged from the baseline scores (1.9 in G1, 2.0 in G2, and 1.9 in G3). Unadjusted hospitalization rates were 19.6%, 27.8% vs 20.8%, and adjusted rates were 44.5%, 56.1% and 47.8% in 3 groups respectively ( Figure) . G2 had a 60% increase in risk of hospitalization after adjustment (odds ratio (OR)=1.60, 95% CI: 1.11-2.29, P = 0.01) compared with G1 but no statistically significant difference compared with G3 (OR=1.40, P = 0.08). Cerebrovascular disease (OR=1.8, P < 0.02), COPD (OR=1.60, P < 0.01), cystic fibrosis (OR=5.85, P < 0.01), depression (OR=1.64, P < 0.05), and other lung disease (OR=1.42, P < 0.05) were associated with a higher risk of hospitalization at year 2 after NTMLD diagnosis.
Conclusion. We observed a lower hospitalization rate in NTMLD patients receiving antibiotics that were concordant with first line ATS/IDSA guidelines recommendations in comparison with those who used other antibiotic regimens.
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Reduction in Nontuberculous Mycobacteria at a Tuberculosis Hospital Following a Quality Assurance Intervention
Quratulain Kizilbash, MD, MPH1; Kenneth Jost, PhD 2 ; Lisa Armitige, MD, PhD 3 ; David E. Griffith, MD 4 ; Denise Dunbar, PhD 2 and Barbara Seaworth, MD, FIDSA from August 1 st , 2016 to January 31 st , 2017, the 6 months following the quality assurance intervention were included. Sputum samples were processed at the Texas Department of State and Health Services (DSHS) Laboratory.
Results. A total of 1,853 sputum samples were processed; 1,288 from 2014 and 565 following the intervention. NTM decreased from 56 (4.3%) to 7 (1.2%) after the quality assurance intervention was instituted for a NTM decrease of 75.0%. M. gordonae decreased by 78.6%. No patients had evidence of NTM disease.
Conclusion. A breach in sputum collection protocols at TCID accounted for the increase in NTM isolation in 2014, half of which were M. gordonae. The reeducation of respiratory therapy staff and initiation of sterile saline rinse prior to sputum collection resulted in a significant reduction in the overall NTM rate. M. gordonae was isolated only three times following the intervention. At TCID, a location where tap water and bottled water contains NTM, drinking these prior to sputum collection possibly contributed to the cluster for NTM, especially M. gordonae. We recommend rinsing the mouth with sterile saline or water prior to sputum collection to decrease isolation of rarely pathogenic NTM.
Disclosures. Background. M. abscessus complex strains are increasingly identified from immunosuppressed hosts, including those patients with cystic fibrosis and those undergoing transplantation. However, the treatment of M. abscessus infections is complicated as a result of its intrinsic resistance to antituberculosis agents and its acquisition of macrolide resistance. Here, we used whole genome sequencing (WGS) coupled with in vitro (7H9) and ex vivo(THP-1 cells) susceptibility studies to explore the activity of ceftaroline (CPT) and imipenem (IMI), alone, or in combination with avibactam (AVI).
Methods. In the current study, 25 clinical isolates of the M. abscessus complex were compared by whole genome sequence analysis, and tested in vitro for susceptibility to CPT and IMI with or without AVI. Using a broth microdilution assay with 7H9 media, a range of drug concentrations from 0.25 to 128 µg/mL, was evaluated with and without AVI at a constant concentration of 4 µg/mL. On the basis of the MIC findings, we also analyzed the bactericidal activity of drug combinations against four clinical isolates (3 M. abscessus and 1 M. bolletii)in human THP-1 cells at an MOI of 1 organism to 10 cells. Bacteria were enumerated at 0, 24hr, 48hr and 72 hours post infection.
Results. WGS results distinguished the 25 M. abscessus complex into three clusters as M. massiliense, M. bolletii, and M. abscessus. Additionally, up to 16 amino acid substitutions were identified in the AmpC (bla MAB ) gene. CPT MICs ranged from 0.5 to 128 µg/mL, but the MIC range was dramatically lowered to <0.125-16 µg/mL in the presence of AVI. IMI activity, in vitro, alone or in combination with AVI ranged from 0.5 to 16 µg/mL. Activity of CPT with AVI in THP-1 cells correlates with the in vitroactivity against all 4 clinical isolates, while the activity of IMI with AVI in THP-1 cells was strain dependent. Increasing concentrations of AVI was active against one strain and had no effect on another strain.
Conclusion. These findings indicate that the in vitro activity of CPT in combination with AVI is predictive for ex vivo activity in human THP-1 cells and this combination may prove to be an effective regimen in treating infections caused by M. abscessus complex. October 7, 2017: 12:30 PM Background. Mycobacterium abscessus infections are increasingly common and can be challenging to treat due to antimicrobial resistance. Clofazimine (CFZ), which is commonly used for treatment of leprosy, comes as a 50 mg capsule that must be swallowed whole. It has excellent in vitro activity against M. abscessus but there are limited reports of its use, particularly in children. During a healthcare associated outbreak of M. abscessus odontogenic infections, 27 children were treated with a CFZ containing regimen for several months.
Methods. Data was collected on all children who received CFZ for a proven or probable M. abscessus odontogenic infection via a Food and Drug Administration Investigational New Drug Application. Demographic, diagnostic and therapeutic information was evaluated, as were laboratory results, adverse events and clinical outcomes.
Results. Of 27 children who received CFZ, 13 were male, 22 were Hispanic and mean age at initial dosing was 5.8 years (range 3.0 -9.4 years). Patients also received azithromycin, amikacin and either imipenem or cefoxitin, though the β-lactam was stopped an average of 31 days after CFZ started. All 27 children had osteomyelitis of the jaw and received aggressive surgical debridement; 10 had a positive stain for acid-fast bacilli (AFB) and 14 had a positive AFB culture (13 M. abscessus, 1 M. chelonae) . Lung nodules were present in 16 children and granulomatous lymphadenitis requiring surgery in 10. Patients received a mean of 105.6 total days of CFZ therapy (range 84-164 days) with a mean weekly dose of 7.6 mg/kg and with dosing occurring a mean of 3 days a week. Every child was able to swallow the CFZ capsule. Minor skin discoloration was noted in 6 children, dry skin in 17, and gastrointestinal symptoms in 11. No child had a clinically significant change in corrected QT interval. All children showed evidence of jaw healing and resolution of lymphadenitis at the end of therapy, and 14 had resolved or improving lung nodules.
Conclusion. This is the largest reported case series of children receiving clofazimine for reasons other than leprosy. It is also the largest report of clofazimine use for extra pulmonary M. abscessus infections. Clofazimine appears to be safe in children and may be an effective part of a surgical and multi-drug regimen for M. abscessus infections.
Disclosures. Saturday, October 7, 2017: 12:30 PM Background. Leprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and preventable disability affecting hands, feet and eyes. TNF-α is the main inflammatory cytokine associated. Type 1 Reactions are treated with oral corticosteroids. There is little evidence on alternative treatments for patients who do not respond to steroids or experience steroid adverse effects. We report the results of a randomized controlled trial testing the efficacy and adverse effect profile of Anti-TNF α Bio-similar Adalimumab and prednisolone in comparison to prednisolone only in patients with new T1R. Outcomes were measured using a clinical severity score, recurrence rate, adverse events and quality of life.
Methods. Seventy-three patients with new T1R were randomized to receive Adalimumab or Prednisolone for 20 weeks. TNF-α levels were corelated before and after the intervention.
Results. Recovery rates in skin signs was similar in both groups (91% vs 88%). Improvements in nerve function both, new and old, sensory (66% vs 49%) and motor (75% vs 74%) loss were higher (but not significantly so) in the patients on Adalimumab. Recurrences rates of T1R (85%) were high in both groups, and recurrences occurred significantly earlier (8 weeks) in patients Adalimumab, who needed 10% more additional prednisolone. Serious major and minor adverse events rates were much lesser with Adalimumab as compared with Prednisolone alone. Both groups had a significant improvement in their quality of life after the study, measured by the Short form survey SF-36.
Conclusion. This is the first double-blind RCT assessing adalimumab, in the management of T1R. It could be a safe alternative second-line drug for patients with T1R who are not improving with prednisolone or are experiencing adverse events related to prednisolone. TNF-α levels could be an important diagnostic marker to diagnose and prognisticate cases of Type 1 Lepra reaction, which if not treated in time can lead to irreversible nerve damage.
Disclosures. All authors: No reported disclosures. October 7, 2017: 12:30 PM Background. Nontuberculous Mycobacteriae (NTM) are widely distributed in natural environments and are known to cause human diseases distinct from tuberculous mycobacteria. NTM caused diseases may lead to significant morbidity and mortality, particularly in immunocompromised hosts such as cancer patients. We present here a 5-year experience of NTM isolates at the Moffitt Cancer Center and research institute in Tampa, Florida.
Nontuberculous Mycobacteria Isolates at a Cancer
Methods. We conducted a single center, retrospective study of patients with NTM from January 2011 to February 2016. Records were searched to identify patients with NTM. Specimens included bronchial lavage, swabs, blood, body fluids and biopsy or excised surgical specimens. Basic demographics of patients, clinical attributes, presentation and sites from which the NTM were isolated and associated neoplastic pathologies were evaluated for each NTM type and compared.
